Vaccine strategies to treat lymphoproliferative disorders

Lymphoproliferative disorders, including follicular lymphoma (FL), multiple myeloma (MM) and chronic lymphatic leukaemia (CLL), are slowly progressive malignancies which remain incurable despite advances in therapy. Harnessing the immune system to recognise and destroy tumours is a promising new app...

Full description

Saved in:
Bibliographic Details
Published in:Pathology 2005-12, Vol.37 (6), p.534-550
Main Authors: Radford, Kristen J., Vari, Frank, Hart, Derek N.J.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
chronic lymphocytic leukaemia
clinical trials
Clinical Trials as Topic
Dendritic cells
Dendritic Cells - immunology
Dendritic Cells - pathology
follicular lymphoma
Hematologic and hematopoietic diseases
Humans
immunotherapy
Investigative techniques, diagnostic techniques (general aspects)
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Follicular - immunology
Lymphoma, Follicular - pathology
Lymphoma, Follicular - therapy
Lymphoproliferative Disorders - immunology
Lymphoproliferative Disorders - pathology
Lymphoproliferative Disorders - therapy
Medical sciences
multiple myeloma
Multiple Myeloma - immunology
Multiple Myeloma - pathology
Multiple Myeloma - therapy
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Vaccination
vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphoproliferative disorders, including follicular lymphoma (FL), multiple myeloma (MM) and chronic lymphatic leukaemia (CLL), are slowly progressive malignancies which remain incurable despite advances in therapy. Harnessing the immune system to recognise and destroy tumours is a promising new approach to treating these diseases. Dendritic cells (DC) are unique antigen-presenting cells that play a central role in the initiation and direction of immune responses. DC loaded ex vivo with tumour-associated antigens and administered as a vaccine have already shown promise in early clinical trials for a number of lymphoproliferative disorders, but the need for improvement is widely agreed. Recent advances in the understanding of basic DC biology and lessons from early clinical trials have provided exciting new insights into the generation of anti-tumour immune responses and the design of vaccine strategies. In this review we provide an overview of our current understanding of DC biology and their function in patients with lymphoproliferative disorders. We discuss the current status of clinical trials and new approaches to exploit the antigen presenting capacity of DC to design vaccines of the future.
ISSN:0031-3025
1465-3931
DOI:10.1080/00313020500376462